177Lu-PSMA靶向治疗中的外照射、排泄与有效半衰期
该双中心回顾性研究纳入50例接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者(平均给药活度6.3±0.5 GBq),测量2米处全身剂量率并计算有效半衰期,另对25例患者行7个时间点全身测量以估算排泄活度。结果显示给药后4小时约50%、12小时约70%的活度主要经尿排泄,队列平均有效半衰期为40.5±9.6小时。作者结论认为就公众辐射暴露而言177Lu-PSMA是安全的核素治疗选择,但需确保符合法规要求,某些国家强制要求患者住院。
要点
- 给药后4小时约50%、12小时约70%的活度主要经尿排泄。
- 2米处平均剂量率:给药后2小时3.6±0.7 μSv/h,24小时1.6±0.6 μSv/h,48小时1.1±0.5 μSv/h,72小时0.7±0.4 μSv/h。
- 队列平均有效半衰期为40.5±9.6小时(最小21.7小时,最大85.7小时)。
核心结论
- 就公众辐射暴露而言,177Lu-PSMA是安全的核素治疗选择。
- 通常进行四个(有时更多)周期的治疗,必须以确保能遵守适用法律要求的方式进行。
- 公众辐射暴露和废水中活度浓度必须低于限值,因此某些国家强制要求这些患者住院。
研究设计与样本
- 双中心回顾性研究,共纳入50例接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者,平均给药活度6.3±0.5 GBq。
- 在给药后多个时间点于2米距离测量全身剂量率,计算并比较不同时间点的有效半衰期。
- 采用剂量积分估算公众辐射暴露;对25例患者在7个时间点行全身测量以估算排泄活度。
主要发现
- 未结合的177Lu-PSMA-617从体内快速清除,给药后4小时约50%、12小时约70%的给药活度被排泄,主要经尿排泄。
- 2米处平均剂量率:给药后2小时3.6±0.7 μSv/h,24小时1.6±0.6 μSv/h,48小时1.1±0.5 μSv/h,72小时0.7±0.4 μSv/h。
- 队列平均有效半衰期为40.5±9.6小时(最小21.7小时,最大85.7小时)。
- 患者于临床48小时后出院时,每个治疗周期对公众个体的最大剂量约为250±55 μSv;72小时后出院时约为190±36 μSv。
临床怎么用
- 作者结论认为就公众辐射暴露而言177Lu-PSMA是安全的核素治疗选择。
- 通常进行四个(有时更多)周期的治疗,必须以确保能遵守适用法律要求的方式进行。
- 公众辐射暴露和废水中活度浓度必须低于限值,因此某些国家强制要求这些患者住院。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. RESULTS: In total, 50 patients with mCRPC and treated with 177Lu-PSMA-617 (mean administered activity 6.3 ± 0.5 GBq) were retrospectively included in a bi-centric study. Whole-body dose rates were measured at a distance of 2 m at various time points after application of 177Lu-PSMA-617, and effective half-lives for different time points were calculated and compared. Radiation exposure to the public was approximated using the dose integral. For the estimation of the excreted activity, whole body measurements of 25 patients were performed at 7 time points. Unbound 177Lu-PSMA-617 was rapidly cleared from the body. After 4 h, approximately 50% and, after 12 h, approximately 70% of the administered activity were excreted, primarily via urine. The mean dose rates were the following: 3.6 ± 0.7 μSv/h at 2 h p. i., 1.6 ± 0.6 μSv/h at 24 h, 1.1 ± 0.5 μSv/h at 48 h, and 0.7 ± 0.4 μSv/h at 72 h. The mean effective half-life of the cohort was 40.5 ± 9.6 h (min 21.7 h; max 85.7 h). The maximum dose to individual members of the public per treatment cycle was ~ 250 ± 55 μSv when the patient was discharged from the clinic after 48 h and ~ 190 ± 36 μSv when the patient was discharged after 72 h. CONCLUSIONS: In terms of the radiation exposure to the public, 177Lu-PSMA is a safe option of radionuclide therapy. As usually four (sometimes more) cycles of the therapy are performed, it must be conducted in a way that ensures that applicable legal requirements can be followed. In other words, the radiation exposure to the public and the concentration of activity in wastewater must be sub-marginal. Therefore, in certain countries, hospitalization of these patients is mandatory.
引用
- Kurth J, Krause BJ, Schwarzenböck SM, et al. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res. 2018. PMID: 29651569. doi:10.1186/s13550-018-0386-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。